## 3 Results
### Analysis Part
#### 3.2.2 Temporal In Vitro Stability Tests of All DFMACs in Simulated Body Fluids
In 0.9% NaCl solution, particles of DFMACs exhibit  
\begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline
**Time** & \multirow{2}{*}{**AMP**} & \multirow{2}{*}{**CEF**} & **PMVEMA-** & **PIBMA-** & **PEMA-** & **PMVEMA-** & **PIBMA-** & **PEMA-** \\
**(min)** & & & **AMP** & **AMP** & **AMP** & **CEF** & **CEF** & **CEF** \\ \hline
0 & 0.32 & 0.37 & 0.40 & 0.38 & 0.33 & 0.35 & 0.41 & 0.34 \\
15 & 0.36 & 0.31 & 0.45 & 0.47 & 0.45 & 0.33 & 0.38 & 0.30 \\
30 & 0.43  
ited more homogenous distribution than the particles of drugs. Ensuring homogenous distribution is crucial for the efficiency, stability and safety of drugs [31]. \begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline
**Time** & **AMP** & **CEF** & **PMVEMA-AMP** & **PIBMA-AMP** & **PEMA-AMP** & **PMVEMA-CEF** & **PIBMA-CEF** & **PEMA-CEF** \\ \hline
0 & \(-14.8\) & \(-13.4\) & \(-31.3\) & \(-16.8\) & \(-32.5\) & \(-30.4\) & \(-22.1\)  
Table 12 indicates that particles of drugs and DFMACs formed clusters at the end of the three-week period. Clusters of particles of AMP aggregated and precipitated and the size of the particles became smaller after the first week, supported by the low mobility values in Table S4. On the other hand, CEF and DFMACs did not precipitate in the three-week period, but formed clusters. The small particle size results in the high absolute mobility values as demonstrated by Table 12 and Table S4. In Table 13, zeta potential values of all particles, regardless of sign, showed a decreasing trend in general. Very low zeta potential values of the drug were compensated and stabilized by copolymer conjugation, especially after the second day. PMVEMA and PEMA conjugation increased the zeta potential values and the stability significantly. In Figure 10, it was evident that drugs have the lowest absolute zeta potential values overall. The absolute zeta potential values of all samples decreased with time. Hence, all DFMACs in this research were analyzed considering time and pH change in various simulated body fluids such as 5% dextrose solution, phosphate-buffered saline (PBS) solution and 0.9% NaCl solution. Among the tested body fluids, 5% dextrose solution  
\begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline
**Time** & **AMP** & **CEF** & **PMVEMA-AMP** & **PIBMA-AMP** & **PEMA-AMP** & **PMVEMA-CEF** & **PIBMA-CEF** & **PEMA-CEF** \\ \hline
0 & \(-9.6\) & \(-16.9\) & \(-25.6\) & \(-15.6\) & \(-27.1\) & \(-31.9\) & \(-22.4\) & \(-26.9  
and 0.9% isotonic NaCl solution led to more stable results for DFMACs compared to PBS solution due to the basicity of this solution. Since the pH value and the chemical composition of the medium imitate the GI, the order of the GI from stomach to colon is crucial. The drugs and DFMACs were first exposed to a highly acidic medium with 0.9% isotonic NaCl solution, simulating conditions similar to the stomach, and subsequently to a basic pH environment with PBS solution, resembling conditions found in the colon. In this order, drugs and DFMACs should be stable, active, monodispersed and mobile, as long as possible to be efficient. However, drugs were active in acidic conditions, but unstable in acidic conditions and susceptible to dissolution in gastric media. On the other hand, DFMACs met the requirements by demonstrating prolonged stability, activity and mobility, making them efficient alternatives to those drugs.